Invited critical reviewDiagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications
Introduction
Worldwide, hepatocellular carcinoma (HCC) is the 5th most common cancer and the 3rd most important cause of cancer mortality, with a 5-year survival rate of merely 7% [1], [2]. HCC develops on a background of a chronically diseased liver, called a cirrhotic liver. Since HCC is a disease with a very poor prognosis due to resistance to conventional chemotherapy, and mostly diagnosed at an advanced stage when most potentially curative therapies are of limited efficacy; close follow-up of patients with cirrhosis is important in order to detect HCC at an early stage. Early detection enables us to provide the patient with the most optimal therapy [3], [4]. Current conventional methods for diagnosis and screening include physical examination, ultrasound imaging and serum alpha-fetoprotein (AFP) concentration measurements in high-risk patients. Despite the fact that serum AFP is still the golden standard amongst diagnostic markers for HCC, its diagnostic value is more and more questioned, due to poor sensitivity and specificity of the assay. As a result, research has focussed on AFP related parameters, like AFP mRNA and AFP glycoforms. For the last two decades, these related parameters have been extensively studied for use as potential new markers for diagnosis and monitoring of HCC. This review summarizes the present knowledge on AFP and its related parameters in diagnosing and monitoring HCC.
Section snippets
Synthesis and genetics
Alpha-fetoprotein was discovered in 1956 by Bergstrand and Czar using paper electrophoresis of human foetus serum proteins [5]. However, it was only in 1963 that AFP gained interest after discovery of AFP in adults during carcinogenesis [6]. The human alpha-fetoprotein gene is mapped on chromosome 4 (4q11–q13) and is part of the albuminoid gene superfamily which encodes, besides AFP, for several other proteins, including albumin and vitamin D-binding protein [7], [8]. AFP is synthesized by the
Immunoassays
Since Tatarinov detected AFP in serum of patients with hepatoma [41], serum AFP has developed to the most common diagnostic marker for HCC. The first conditionally quantitative serum assays for AFP were introduced in 1971 [10]. The association between serum AFP and HCC has been extensively described [6], [10], [42], [43], [44], [45], [46]. However, despite this clear association, sensitivity and specificity for this assay are poor [47] and vary according to study design, patient population and
Clinical aspects
In adult life, AFP synthesis is repressed. Elevated AFP serum levels are only seen in maternal serum during pregnancy, in certain tumours (e.g. HCC, gastric carcinoma, lung cancer, pancreatic cancer and testicular carcinoma) [78], [79], [80], [81], [82] and non-tumoral conditions (e.g. chronic hepatitis and liver cirrhosis) [83], [84], [85].
Summary and conclusions
Although sometimes called ‘obsolete’, measuring AFP concentration in the blood remains the easiest and preferred serum tumour marker for screening and diagnosing HCC in a clinical setting. AFP glycoforms show promising results as clinically useful HCC markers. AFP-L3, alone or in combination with AFP-P4 + P5, is an interesting parameter in this respect. Due to its high specificity it can be used complementary to the total serum AFP assay for early tumour recognition, diagnosis, follow-up after
Acknowledgement
EDB received a scholarship GOA BOFF07/GOA/017 from the University Ghent Research Fund (BOF).
References (128)
- et al.
Epidemiology of hepatocellular carcinoma
Clin Liver Dis
(2005) - et al.
Hepatocellular carcinoma in the Netherlands incidence, treatment and survival patterns
Eur J Cancer
(2004) - et al.
Induction of remission in hepatocellular carcinoma with doxorubicin
Lancet
(1978) - et al.
The vitamin D-binding protein, alpha-fetoprotein, albumin multigene family: detection of transcripts in multiple tissues
J Biol Chem
(1989) Chemistry and biology of alpha-fetoprotein
Adv Cancer Res
(1991)- et al.
Human-fetoprotein. Isolation, characterization, and demonstration of microheterogeneity
J Biol Chem
(1972) - et al.
Microheterogeneity of rat, mouse and human alpha1-fetoprotein as revealed by polyacrylamide gel electrophoresis and by crossed immuno-affino-electrophoresis with different lectins
Biochim Biophys Acta
(1979) Alpha-fetoprotein: separation of two molecular variants by affinity chromatography with concanavalin A-agarose
Biochim Biophys Acta
(1973)- et al.
Carbohydrate structure of the concanavalin A molecular variants of alpha-fetoprotein
J Biol Chem
(1982) - et al.
Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma
Biochim Biophys Acta
(1985)
A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients
Hepatology
Identification of alpha-fetoprotein polymers. Artifacts of the isolation procedure
Clin Chim Acta
Alpha-fetoprotein in human hepatoma: improved detection in serum, and quantitative studies using a new sensitive technique
Gastroenterology
Serum-alpha-foetoprotein and primary hepatic cancer
Lancet
Foetoglobin and primary liver cancer
Lancet
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver
J Hepatol
Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status
J Hepatol
Alphafetoprotein: an obituary
J Hepatol
Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation
Am J Gastroenterol
Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis
J Hepatol
Simultaneous determination of percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein and alpha-fetoprotein concentration using the LiBASys clinical auto-analyzer
Clin Chim Acta
Alpha-fetoprotein-concanavalin A binding as a marker to discriminate between germ cell tumours and liver diseases
Eur J Cancer
Spontaneous and iatrogenic spreading of liver-derived cells into peripheral blood of patients with primary liver cancer
Hepatology
Highly-sensitive identification of alpha-fetoprotein mRNA in circulating peripheral blood of hepatocellular carcinoma patients
Life Sci
Presence of alpha-fetoprotein mRNA in blood correlates with outcome in patients with hepatocellular carcinoma
J Hepatol
Quantitative comparison of alpha-fetoprotein and albumin mRNA levels in hepatocellular carcinoma/adenoma, non-tumor liver and blood: implications in cancer detection and monitoring
Cancer Lett
Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma
Surgery
Elevated serum tumor markers in patients with testicular cancer after induction chemotherapy due to a reservoir of markers in cystic differentiated mature teratoma
J Urol
Primary lung cancer producing alpha-fetoprotein
Ann Thorac Surg
Alpha-fetoprotein (AFP) in benign liver disease. Evidence that normal liver regeneration does not induce AFP synthesis
Gastroenterology
Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis
J Hepatol
Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions
Gastroenterology
AFP-L3: a new generation of tumor marker for hepatocellular carcinoma
Clin Chim Acta
Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas
Gastroenterology
Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma
Am J Gastroenterol
Serum alpha fetoprotein heterogeneity as a means of differentiating between primary hepatocellular carcinoma and hepatic secondaries
Clin Chim Acta
New therapies for hepatocellular carcinoma
Oncogene
Demonstration of a new protein fraction in serum from the human fetus
Scand J Clin Lab Invest
Production of embryonal alpha-globulin by transplantable mouse hepatomas
Transplantation
Screening for hepatocellular carcinoma
J Vasc Interv Radiol
Tumour markers
Studies of carcino-fetal proteins. 3. Development of a radioimmunoassay for alpha-fetoprotein. Demonstration of alpha-fetoprotein in serum of healthy human adults
Int J Cancer
Structure of the asparagine-linked sugar chains of alpha-fetoprotein purified from human ascites fluid
Cancer Res
Alpha-fetoprotein as a biologic response modifier: relevance to domain and subdomain structure
Proc Soc Exp Biol Med
Microheterogeneity of human alphafetoprotein
Tumour Biol
Structural and functional mapping of alpha-fetoprotein
Biochemistry (Mosc)
Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants
Exp Biol Med (Maywood)
Detection of hepatocellular carcinoma-specific alpha-fetoprotein by isoelectric focusing
Cancer
‘Hepatoma-specific’ alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease
Br J Cancer
Alpha-fetoprotein: reevaluation in hepatology
Hepatology
Cited by (204)
Impact of radiation therapy and alpha-fetoprotein level on survival outcomes for patients with hepatocellular carcinoma: A population-based study
2023, Clinics and Research in Hepatology and GastroenterologyDevelopment of advanced diagnostic platform for detection of infectious diseases
2023, Molecular Pharmaceutics and Nano Drug Delivery: Fundamentals and ChallengesNanotechnology-based approaches for effective detection of tumor markers: A comprehensive state-of-the-art review
2022, International Journal of Biological MacromoleculesLPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinoma
2022, Genes and DiseasesCitation Excerpt :In recent years, molecular marker detection, a convenient and noninvasive method of examination, has attracted wide attention. A large number of molecular markers such as AFP, Ki-67, AFP-L3, PIVKA-II, β-catenin, etc. have been shown to be associated with the diagnosis and prognosis of HCC.8–17 Unfortunately, most of these molecular markers lack sensitivity and specificity.
Hepatitis B virus DNA methylation and its potential role in chronic hepatitis B
2023, Expert Reviews in Molecular Medicine